Skip to main content
. 2016 Jun 7;28(2):152–162. doi: 10.1097/MBC.0000000000000568

Fig. 1.

Fig. 1

Study participant disposition. aFor PK study participants with type 3 von Willebrand disease only. PK, pharmacokinetics.